AZ's Fasenra Gets Boost From Steroid-Sparing Data

Expansion Plans For Big-Selling Biologic

 
• By Kevin Grogan

The POTENTE trial demonstrated Fasenra’s impact in eliminating or reducing oral corticosteroid use for severe asthma patients, which should help AstraZeneca as it takes on GlaxoSmithKline’s rival IL-5 inhibitor, Nucala.

Sodertalje, Sweden - April 27, 2014: Three purple flags with the logo for Atrazeneca flying in the wind on top of the flagpoles against the blue sky.
Flying the flag for Fasenra • Source: Shutterstock

More from Respiratory

More from Therapy Areas